Calcium/Vitamin D

DIETARY_SUPPLEMENT6 trials

Sponsors

Amgen, Novartis, University Hospital of Mont-Godinne, United States Army Research Institute of Environmental Medicine, Massachusetts General Hospital

Conditions

Bone AlterationBone HealthDietary ModificationGCTGiant Cell Tumor of BoneNutrition StatusObesityOsteopenia

Phase 2

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

CompletedNCT00396279

AmgenGCT, Giant Cell Tumor of Bone

Start: 2006-07-10End: 2011-02-01Updated: 2022-11-08

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

RecruitingNCT05933499

Massachusetts General HospitalObesity

Start: 2025-11-05End: 2029-03-31Target: 63Updated: 2026-03-27

Phase 3

Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis

CompletedNCT00404820

NovartisOsteoporosis

Start: 2006-10-31End: 2008-12-31Updated: 2011-07-01

Osteoporosis Prevention With Low Dose Alendronate

CompletedNCT00463268

University Hospital of Mont-GodinneOsteopenia

Start: 2007-09-30End: 2012-01-31Updated: 2013-05-29

Unknown Phase

Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture

CompletedNCT02375503

United States Army Research Institute of Environmental MedicineBone Alteration, Dietary Modification

Start: 2015-04-30End: 2015-06-30Updated: 2017-05-15

Evaluation of Calcium and Vitamin D Supplementation During Marine Corps Training

CompletedNCT02636348

United States Army Research Institute of Environmental MedicineBone Health, Nutrition Status

Start: 2015-07-31End: 2016-10-31Updated: 2016-10-28

Related Papers

A dietary pattern rich in calcium, potassium, and protein is associated with tibia bone mineral content and strength in young adults entering initial military training.

2019-01-0112 citations

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.

2018-09-1937 citations

Response to treatment with denosumab in patients with giant cell tumor of bone (GCTB): FDG PET results from two phase 2 trials.

Journal of Clinical Oncology2014-05-206 citations

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

2010-02-10465 citations